Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors

Bibliography

• Poh C, Gasiorowska A, Fass R, Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endoscop 2010;71(1):28-34
   Google Scholar
• Boeckxstaens GE. Reflux inhibitors: a new approach for GERD?. Curr Opin Pharmacol 2008;8:1-5
   Web of Science ®Google Scholar
• Kaywood C, Wakefield M, Tack J, A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 2009;58:1192-9
   PubMed Web of Science ®Google Scholar
• Boeckxstaens GE. Emerging drugs for gastroesophageal reflux disease. Exp Opin Emerg Drug 2009;14:481-91
   PubMed Web of Science ®Google Scholar
• Dent J. Roles of gastric acid and pH in the pathogenesis of gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl 1994;201:55-61
   PubMedGoogle Scholar
• Armstrong D. Review article: gastric pH – the most relevant predictor of benefit in reflux disease?Aliment Pharmacol Ther 2004;20(Suppl 5):19-26
   PubMedGoogle Scholar
• Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9(Suppl 1):3-7
   PubMed Web of Science ®Google Scholar
• Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999;159:649-57
   PubMed Web of Science ®Google Scholar
• Katz PO, Ginsberg GG, Hoyle PE, Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2007;25:617-28
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Dent J, Lauritsen K, A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007;5:1385-91
   PubMed Web of Science ®Google Scholar
• Dent J, Kahrilas PJ, Hatlebakk J, A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008;103:20-6
   PubMed Web of Science ®Google Scholar
• Sharma P, Shaheen NJ, Perez MC, Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation – results from two randomized controlled studies. Aliment Pharmacol Ther 2009;29:731-41
   PubMed Web of Science ®Google Scholar
• Orlando RC. Esophageal damage and repair in GERD. J Clin Gastro 2007;41:S108-13
   Web of Science ®Google Scholar
• Bredenoord AJ. Lesogaberan, a GABAB agonist for the potential treatment of gastroesophageal reflux disease. IDrugs 2009;12:576-84
   PubMedGoogle Scholar
• Smid S, Young R, Cooper N, Blackshaw L. GABAB expressed on vagal afferent neurons inhibit gastric mechanosensitivity in perret proximal stomach. Gastro Liver Physiol 2001;281:G1494-501
   PubMed Web of Science ®Google Scholar
• Lee KJ, Vos R, Janssens J, Tack J. Differential effects of baclofen on lower oesophageal sphincter pressure and proximal gastric motility in humans. Aliment Pharmacol Ther 2003;18:199-207
   PubMed Web of Science ®Google Scholar
• Van Herwaarden MA, Samson M, Rydholm H, Smout AJPM. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther 2002;16:1655-62
   PubMed Web of Science ®Google Scholar
• Aronoff GM, Gallagher RM, Patel JG. Pharmacological management of chronic pain: a review. In: Tollison JW, Satterhwaite JR, editors. Practical pain management. Lippincott, Williams & Wilkins, Philadelphia, PA; 2002. p. 253-78
   Google Scholar
• Takeuchi K, Nishiwaki H, Niida H, Body temperature-dependent action of baclofen in rat stomach. Relation to acid secretion and ulcerogenicity. Dig Dis Sci 1990;35:458-66
   PubMed Web of Science ®Google Scholar
• Piqueras L, Martinez V. Peripheral GABAB agonists stimulate gastric acid secretion in mice. Br J Pharmacol 2004;142:1038-48
   PubMed Web of Science ®Google Scholar
• Lehmann A, Antonsson M, Holmberg A, (R)-(3-Amino-2-fluoropropyl) Phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action. J Pharmacol Exper Ther 2009;331:504-12
   PubMed Web of Science ®Google Scholar
• Lehmann A, Blackshaw LA, Elebring T, The new reflux inhibitor AZD3355 has a low propensity for inducing central side effects due to its affinity for the GABA carrier. Gastroenterol 2008;134(4)(Suppl 1):A715-6
   Web of Science ®Google Scholar
• Lehmann A, Blackshaw LA, Elebring T, The new reflux inibitor AZD3355 has a low propensity for inducing central side effects due to its affinity for the GABA carrier. European Gastroenterology Week, Vienna, Austria, 21 October 2008:abstract OP266
   Google Scholar
• McDermott CM, Abrahams TP, Partosoedarso E, Site of action of GABA(B) receptor for vagal motor control of the lower esophageal spincter in ferrets and rats. Gastroenterology 2001;120:1749-62
   PubMed Web of Science ®Google Scholar
• Boeckxstaens GE, Denison H, Ruth M, Effect of AZD3355, a novel GABAB agonist, on reflux and lower esophageal sphincter function in patients with GERD with symptoms despite proton pump inhibitor treatment. Dig Dis Week Chicago, IL, USA, 1 June 2009;136: abstract M1861
   Google Scholar
• Fransson B, Silberg DG, Niazi M, Effect of food on the bioavailability of AZD3355, a novel reflux inhibitor, in healthy subjects. Dig Dis Week, Chicago, IL, USA, 1 June 2009;135: abstract M1911
   Google Scholar
• Lal R, Sukbuntherng J, Tai E, Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. J Pharmacol Exp Ther 2009;330(3):911-21
   PubMed Web of Science ®Google Scholar
• Gerson L, Huff F, Hila A, Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 2009. [Epub 29 Dec 2009]
   Google Scholar
• Vakil N, Huff J, Bian A, Arbaclofen placarbil monotherapy decreases GERD symptoms in subjects with previous PPI therapy. DDW 2009 Conference, Chicago, IL, USA, 1 June 2009
   Google Scholar
• Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005;108:294-307
   PubMed Web of Science ®Google Scholar
• Dent J, Kahrilas PJ, Hatlebakk J, A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008;103:20-6
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Dent J, Lauritsen K, A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007;5:1385-91
   PubMed Web of Science ®Google Scholar
• Arai K, Takeuchi Y, Watanabe H, Prokinetics influence the pharmacokinetics of rabeprazole. Digestion 2008;78:67-71
   PubMed Web of Science ®Google Scholar
• Futagami S, Iwakiri K, Shindo T, The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol 2010;45(4):413-21
   Google Scholar
• Curran MP, Robinson DM. Mosapride in gastrointestinal disorders. Drugs 2008;68:981-91
   PubMed Web of Science ®Google Scholar
• Miwa H, Koseki J, Oshima T, Rikkunshito, a traditional Japanese medicine, may relieve abdominal symptoms in rats with experimental esophagitis by improving the barrier function of epithelial cells in esophageal mucosa. J Gastroenterol 2009. [Epub 18 Dec 2009]
   Web of Science ®Google Scholar
• Suzuki H, Inadomi JM, Hibi T. Japanese herbal medicine in functional gastrointestinal disorders. Neurogastroenterol Motil 2009;21:688-96
   PubMed Web of Science ®Google Scholar